There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Talphera (TLPH – Research Report) and Cardiol Therapeutics (CRDL – Research Report) with bullish sentiments.
Don’t Miss Our End of Quarter Offers:
Talphera (TLPH)
In a report issued on March 31, Naz Rahman from Maxim Group reiterated a Buy rating on Talphera, with a price target of $3.00. The company’s shares closed last Wednesday at $0.55, close to its 52-week low of $0.50.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -23.6% and a 22.0% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Processa Pharmaceuticals, Vertex Pharmaceuticals, and Virpax Pharmaceuticals.
Talphera has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, representing an 843.4% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
Cardiol Therapeutics (CRDL)
Canaccord Genuity analyst Edward Nash maintained a Buy rating on Cardiol Therapeutics yesterday and set a price target of $8.00. The company’s shares closed last Wednesday at $0.91, close to its 52-week low of $0.91.
According to TipRanks.com, Nash is a 5-star analyst with an average return of 13.1% and a 42.6% success rate. Nash covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Madrigal Pharmaceuticals, and Corcept Therapeutics.
Cardiol Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
Read More on TLPH: